CI · Q4 2025 Earnings

Cautious

Cigna

Reported February 5, 2026

30-second summary

FY2025 adjusted EPS landed at $29.84, $0.24 above the ≥$29.60 floor management held all year. FY2025 Cigna Healthcare MCR closed at 84.4%, 20bps above the 84.2% high end of the original 83.2%–84.2% guide — a modest miss; Q4 MCR of 88.0% is essentially flat vs. Q4 2024's 87.9% and reflects normal seasonality (Q1 2026 guided below 81%), not a Q3 trajectory break. The 2026 reset is the real disclosure: headline EPS guide of ≥$30.25 is just +1.4% growth, the FY2026 Evernorth guide of ≥$6,900M sits ~$321M (-4.4%) below FY2025's $7,221M actual reflecting the previously-disclosed "slight decline" from PBS contract repricing and transition investment, and the FY2026 MCR band of 83.7%–84.7% sits 50bps higher at both ends than the original FY2025 frame.

Headline numbers

EPS

Q4 FY2025

$8.08

Revenue

Q4 FY2025

$72.47B

+10.4% YoY

Operating margin

Q4 FY2025

3.0%

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$72.47B	+10.4%	$69.75B	+3.9%
EPS	$8.08	—	$7.83	+3.2%
Operating margin	3.0%	—	—	—

Guidance

FY2025 EPS beat guidance; FY2026 outlook shows modest growth with hidden margin pressure in Evernorth offset by Cigna Healthcare strength and cautious MCR expectations.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
EPS (Non-GAAP)	FY 2025	at least $29.60	$29.84	+$0.24 above guide	Beat

New guidance

Metric	Period	Guide	YoY
Revenue	FY 2025	$280.0 billion	—
EPS (Non-GAAP)	FY 2026	at least $30.25	+1.4% YoY
Adjusted Income from Operations	FY 2026	at least $7.950 billion	—
Adjusted SG&A Expense Ratio	FY 2026	~5.0%	—
Adjusted Effective Tax Rate	FY 2026	~19.0%	—
Cash Flow from Operations	FY 2026	~$9,000 million	—
Total Medical Customers	FY 2026	~18.1 million	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Evernorth Adjusted Income from Operations, Pre-Tax	FY 2026	at least $7,200 million	at least $6,900 million	-$300 million	Raised
Cigna Healthcare Adjusted Income from Operations, Pre-Tax	FY 2026	at least $4,125 million	at least $4,500 million	+$375 million	Raised

Segment KPIs

Q4 FY2025

Segment	Q4 FY2025	YoY
Evernorth Health Services - Pharmacy Benefit Services	$36.339B	+20.0%
Evernorth Health Services - Specialty and Care Services	$26.717B	+13.8%
Cigna Healthcare	$11.172B	-16.2%

Other KPIs

Q4 FY2025

Segment	Q4 FY2025
Total Pharmacy Customers	123.6 million
Total Medical Customers	18.1 million
Total Customer Relationships	188.4 million
Behavioral Care Customers	28.3 million
Evernorth Health Services Operating Margin (Pre-Tax)	3.5%
Cigna Healthcare Medical Care Ratio (MCR)	88.0%
Adjusted SG&A Expense Ratio	4.7%
Debt-to-Capitalization Ratio	43.0%

Management tone

Q2 selling-season confidence → Q3 2026 reset disclosure → Q4 quantified reset and CHC pivot.

The narrative arc resolved this quarter into something specific: Evernorth's 2026 step-down moved from a directional guide ("slight decline") to a quantified ≥$6,900M floor, roughly $321M below the FY2025 $7,221M actual. Management chose not to soften it on the print. David Cordani framed the transition as consistent with the prior guidance, emphasizing that the "underlying growth algorithm for the pharmacy benefit services portion of our portfolio will remain intact" once the new rebate-free model is implemented, and Brian Evanko noted that "investment spending to build the infrastructure required for our transformative rebate-free model" would commence in 2026 with a back-half-weighted cadence.

The regulatory posture shifted from combative (Q2's Arkansas response) to procedural. On the FTC settlement, David Cordani told TD Cowen that the launch plan is unchanged and that there is "no liability that we assume if the adoption rate is above or below" expectations, and that the company will lead with its guaranteed cost book. The Q2 framing of regulators as adversaries has been replaced by a checklist tone — affordability, transparency, consumer advocacy — with management positioning the rebate-free model as the answer. The tax disclosure (GPO move from Switzerland to U.S. could impact effective tax rate "up to 1%" over time if unmitigated) is a new acknowledgment of a structural earnings drag the prior two quarters did not flag.

On MCR, management did not explicitly address the 20bps FY2025 ceiling miss on the print. The FY2026 range simply shifts 50bps higher to 83.7%–84.7%, with Ann Dennison citing pricing actions on stop loss and individual exchange businesses alongside "a cost-trend environment that remains elevated" as the assumptions underlying the new band.

Q&A highlights

Lisa Gill · JPMorgan

Asked about the margin profile of the PBM business in steady state under the new rebate-free model post-FTC settlement and legislation, and inquired about tax implications of moving the GPO from Switzerland to the U.S.

David Cardani confirmed the margin profile will remain similar to legacy models, with no change to the growth algorithm. He stated the GPO move to the U.S. could impact the effective tax rate by up to 1% over time if unmitigated, but characterized this as manageable against long-term earnings growth targets of 10-14%.

Margin profile expected to remain similar between legacy and new rebate-free modelsPBM growth algorithm remains intact through transitionGPO relocation from Switzerland to U.S. could impact tax rate by up to 1% maximumCompany believes impact is manageable against 10-14% long-term earnings growth algorithm

Scott Fidel · Goldman Sachs

Asked whether Cigna believes its PBM model is now fully aligned with regulatory and policymaker expectations or if regulatory battles remain. Also requested clarity on client adoption rates and ramp expectations for the new pricing model through 2028.

David Cardani stated the company is confident its model addresses regulatory priorities around affordability, transparency, and consumer advocacy. Brian Avenko provided adoption details: entire Cigna Healthcare fully insured book adopting in 2027, at least 50% of Evernorth business by end-2028. He emphasized the three core value creators (unit pricing, benefit administration, patient support) remain constant across models.

100% of Cigna Healthcare fully insured book adopting new model in 2027At least 50% of Evernorth business expected to adopt by year-end 2028Early feedback from clients and brokers described as positiveCore value creators remain consistent: securing better unit pricing, administering benefits, supporting patients with clinical programs

Charles Ray · TD Cowen

Asked whether FTC settlement timing aligns with rebate-free model launch. Also inquired about Cigna's responsibility to push the new model on clients and potential liability if clients don't adopt the required settlement offerings.

David Cardani confirmed the launch plan is unchanged by the FTC agreement and no liability attaches to Cigna if adoption rates differ. The company will lead adoption with its guaranteed cost book and make the new model its standard offering in 2028, while maintaining choice in the marketplace. Brian Avenko confirmed price-assured technology guarantees patients the lowest possible out-of-pocket price.

FTC settlement does not change rebate-free model launch plan or milestonesNo liability assumed if adoption rates vary from expectationsNew model includes 'price-assured technology' guaranteeing lowest out-of-pocket priceModel will be standard offering by 2028 while maintaining marketplace choice

Kevin Fishback · Bank of America

Asked why Cigna Healthcare MCR is not expected to improve in 2026 despite repricing and smaller exchange business, and requested guidance on appropriate MCR levels for the fully repriced business.

Ann Dennison explained that 2026 MCR outlook incorporates pricing actions, elevated cost trends, and one-time items that benefited 2025 results. She cited two offsetting factors: reductions from stop-loss pricing and individual business repricing, offset by one-time 2025 items and mixed dynamics. Referred analyst to provided 2026 MCR guidance range of 83.7-84.7%.

2026 Cigna Healthcare MCR guidance range: 83.7%-84.7%2026 assumes elevated cost trend environment and appropriate prudenceStop-loss pricing tracking in line with expectationsIndividual business repriced for margin improvement

Justin Lake · Wolf Research

Asked whether 2027 PBM earnings will be a headwind and conform to long-term growth algorithm. Also inquired about changes to PBM revenue recognition methodology as the business transitions from spread/rebate to fee-based models.

Brian Avenko confirmed the FTC agreement will not impact 2027 financial outlook and the long-term PBM growth algorithm remains intact. He noted 2026-2027 will have investment costs for technology and infrastructure. Regarding revenue recognition, he stated no changes are expected in how PBM revenue is recognized, even with the model transition, though this may be refined over time.

FTC settlement will not impact 2027 financial outlookLong-term PBM growth algorithm remains intact2026-2027 will have investment-related costs for infrastructure build-outNo changes expected to PBM revenue recognition methodology despite business model transition

Answers to last quarter's watch list

Q4 Cigna Healthcare MCR — Q4 printed 88.0%, essentially flat vs. Q4 2024's 87.9% and consistent with seasonal pattern. FY2025 MCR closed at 84.4%, 20bps above the 84.2% ceiling — a modest miss. Management did not explicitly address the miss on the print but reset the FY2026 range 50bps higher to 83.7%–84.7%, with Q1 2026 guided below 81%. Status: Resolved — modest miss

First quantified 2026 EPS framing — FY2026 adjusted EPS guided at ≥$30.25, or +1.4% YoY from the $29.84 FY2025 actual — the most conservative print in this coverage window and well below the stated 10-14% long-term algorithm. Revenue guided to ~$280B (+1.9%). Status: Resolved negatively

Rebate-free model client adoption signal — Management quantified the ramp: 100% Cigna Healthcare fully insured adoption in 2027, at least 50% Evernorth by end-2028. Early client and broker feedback characterized as positive; no specific selling-season conversion rate or named client wins disclosed. Status: Resolved positively

PBS large-client margin floor — Not directly quantified. The FY2026 Evernorth guide of ≥$6,900M is ~$321M (-4.4%) below FY2025's $7,221M actual, which implies but doesn't disclose the PBS-specific margin floor. PBS Q4 pre-tax income was $1.15B (-4% YoY) on +20% revenue, signaling clear margin compression on contract repricing. Status: Continue monitoring

Cash flow back-half loading and capital deployment — FY2025 operating cash flow $9.6B; FY2026 guided to ~$9.0B with the majority again expected in the second half. Capex guided ~$1.3B, dividends ~$1.6B. Specific 2026 buyback dollar target was not disclosed. Status: Continue monitoring

What to watch into next quarter

Q1 2026 Cigna Healthcare MCR landing point — Management guided Q1 2026 MCR to below 81%, consistent with prior-year seasonality. Watch whether Q1 lands inside that frame and whether the implied trajectory keeps the FY band of 83.7%–84.7% credible.

Evernorth PBS revenue and margin disclosure — With Evernorth guided to ~$321M below FY2025 actual, watch whether PBS revenue growth holds the Q4 +20% trajectory or decelerates as contract repricing flows through, and whether segment margin compresses further from FY2025's 3.1%.

FY2026 EPS guide revision direction — A ≥$30.25 floor with +1.4% growth is unusually low. Watch whether management raises the floor at Q1 (consistent with FY2025's pattern of holding then beating ≥$29.60) or holds it flat, which would signal genuine concern about Evernorth transition spend.

Rebate-free model implementation cadence — Watch for specific milestones around the 2027 Cigna Healthcare fully-insured adoption and 2028 Evernorth ramp, plus any named client wins or broker channel signals on the new model's conversion rate.

GPO tax structure execution — The "up to 1%" tax rate impact from the Switzerland-to-U.S. GPO move is a new disclosure. Watch whether the FY2026 ~19.0% effective rate guide is held or revised as the structural move advances.

Sources

Cigna Q4 2025 press release (SEC EX-99.1): https://www.sec.gov/Archives/edgar/data/1739940/000114036126003768/ef20064751_ex99-1.htm
Cigna Q4 2025 earnings call Q&A excerpts

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.